Immunoprotein Diagnostic Testing Market to Value USD 21.28 Billion by 2035, Registering at a 7.54% CAGR – SNS Insider
Austin, United States, June 11, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, the Immunoprotein Diagnostic Testing Market was valued at USD 10.28 billion in 2025 and is projected to reach USD 21.28 billion by 2035, expanding at a CAGR of 7.54% during 2026–2035.
The demand for proper disease diagnosis, monitoring, and effectiveness of its treatment in the areas of autoimmune diseases, infections, hematological cancers, and chronic inflammations is steadily increasing, which is driving the growth of global immunoprotein diagnostic testing market. Targeting biomarkers such as immunoglobulin, free light chain, complement, C-Reactive Protein (CRP), pre-albumin, and haptoglobin and are used to test the performance of immune system. More investment in healthcare facilities, automating laboratories, and the use of advanced immunological assay technology has added to market expansion.
Get a Sample Report of Immunoprotein Diagnostic Testing Market Forecast @ https://www.snsinsider.com/sample-request/5777
Growing Burden of Autoimmune and Chronic Diseases Supporting Market Expansion
Increase in the incidences of autoimmune diseases, chronic infections, blood cancer diseases, and immunodeficiencies has fueled the need for immunoglobulin diagnostic tests. Patients suffering from diseases like multiple myeloma, rheumatoid arthritis, and systemic lupus erythematosus are required to undergo tests involving measurement of levels of IgG, complement proteins, and free light chains, thus driving demand for these tests. Moreover, innovations in CLIA, ELISA, and lab automation technologies have boosted the market growth. Increasing use of immunoglobulin tests for diagnosing diseases, monitoring treatment, and providing customized treatments is propelling market growth further.
Leading Market Players Listed in the Immunoprotein Diagnostic Testing Market Report are:
Immunoprotein Diagnostic Testing Market Segmentation Analysis
By Type
In 2025, the market is dominated by the Immunoglobulin Diagnostic Tests segment, which accounted for 28.15% revenue share. The free light chain diagnostic tests segment is expected to witness the fastest growth during the forecast period due to the growing adoption of techniques to manage multiple myeloma and associated plasma cell disorders.
By Technology
In 2025, the ELISA segment accrued around 42% of the market revenue, which is also the highest market share generation segment, owing to its well-documented clinical utility, availability, affordable cost and wide laboratory adoption. The Chemiluminescence Immunoassay (CLIA) segment is expected to be the fastest-growing segment over the forecast period due to its greater sensitivity, suitability for automation, and faster delivery of results.
By Application
The Infectious Disease Testing segment dominated the market and accounted for the largest share of approximately 32% in 2025 with large volumes of testing for inflammatory and immune-response biomarkers. Oncology Testing segment is projected to register rapid growth on account of the rising usage of immunoprotein biomarkers for the diagnosis, monitoring, and assessing the treatment response of cancer.
By End User
The hospitals & clinical laboratories segment accounted for the largest market revenue in 2025, of around 52%, which can be expedited that these are one of the places with the highest volume of patients and they are equipped with advanced testing infrastructure. The growth of Diagnostic Centers is highest owing to increasing expenditure on outpatient diagnostic services and laboratory investment.
Regional Insights
North America held the maximum share of the global immunoprotein diagnostic testing market in 2025, driven by highly developed healthcare infrastructure, large volumes of diagnostic tests being performed, presence of favorable reimbursement systems, and existence of leading companies including Abbott, Roche Diagnostics, Beckman Coulter, Siemens Healthineers, and Thermo Fisher Scientific.
The Europe Immunoprotein Diagnostic Testing Market is estimated at USD 2.88 billion in 2025 and is expected to reach USD 5.83 billion by 2035, registering a CAGR of 7.30% during 2026–2035. Europe considers as a mature market, primarily due to the growing reimbursement framework and developed laboratory infrastructure, and demand for diagnostics during the predicted period.
The Asia Pacific region is anticipated to achieve the highest CAGR during the forecast period. Factors such as expansion of healthcare infrastructure in China and India, increased adoption of laboratory automation, rising burden of chronic diseases, and awareness on immunoprotein biomarkers are driving the growth of the market. China continues to account for the largest regional contribution, and both India, Japan, and South Korea persist in building diagnostic testing capabilities.
Purchase Single User PDF of Immunoprotein Diagnostic Testing Market Report @ https://www.snsinsider.com/checkout/5777
Recent Developments
Exclusive Sections of the Report (The USPs)
Immunoprotein Diagnostic Testing Market Report Scope
Related Market Reports
Meningitis Diagnostic Testing Market Size Report 2026
Autoimmune Disease Testing Market Growth Analysis 2026
Biomarker Testing Market Size Outlook 2026
Biomarker Testing Services Market Growth Report 2026
Blood Testing Market Size Trends 2026
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.